| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c218f9a7f231eb98305c1ecbf809d644 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-6093
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55555
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B40-20 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57484
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57415
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G06F17-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B5-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B40-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B20-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0011 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6886 |
| filingDate |
2020-03-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8beb2a83ba81b2ad879b1b3bd9fde2c2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5f5fea885fb2a60903c189639d910516
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1ad85a563a5165ca9980df3ae2bffc2a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f17d7020fd7bc02224c204c7a95ca2b7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_537a97c9220511a5dcb6355edf2be204
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6ce6a07f749ce80cfe8b95c05fe2a1bb |
| publicationDate |
2020-09-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2020276289-A1 |
| titleOfInvention |
Patient personalized cancer vaccine |
| abstract |
A personalized cancer vaccine is disclosed. The vaccine is comprised of particles encapsulating neoantigens. The neoantigens are chosen by predicting whether a first neoantigen or a second neoantigen of an individual cancer patient has a stronger binding affinity for a human leukocyte antigen (HLA) complex of the patient and using the neoantigen with the stronger predicted binding affinity. Such a predicting step includes artificial intelligence, statistical modeling, or a combination thereof. Placing the antigen in a particular sized particle is referred to here as Size Exclusion Antigen Presentation Control, (SEAPAC) used in methods of treating the patient using such a personalized cancer vaccine. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2023146516-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113041342-A |
| priorityDate |
2019-03-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |